The headline and article ublished: today, Monday March 4, ran with the headline:
For the first 18 years of my life Dad had delivered to our pit owned terraced home a copy of the Daily Express 6 days a week (The Nudes of the World came on Sunday), and my view of the world was therefore coloured by Tory Lord Beaverbrook.
I’ve long since rejected such dross, but at a petrol forecourt today I spotted a copy of the Daily Express, and bought it. You may remember that a few days ago I railed against childhood diseases, and (happily) reflected that they were less of a problem today than they have been.
“A SIMPLE once-a-day jab which could revolutionize the lives of millions with diabetes is now available on the NHS.
The ground-breaking drug – a longer-lasting type of insulin – costs just £2.20 a day.
In order to keep their diabetes under control, many patients have to inject themselves with insulin several times a day to keep their blood sugar level steady.
But the newly available drug, called Tresiba, makes it easier because it lasts for 40 hours instead of a maximum of 18 hours and is much more stable.
This means sufferers do not have to inject it so often. So if patients happen to miss an injection because of the demands of their busy lives they are less likely to suffer the potentially fatal low blood sugar “crash” called hypoglycaemic shock.
Doctors have hailed the new treatment, also known as insulin degludec, as a breakthrough. It can be used to manage both Type 1 and Type 2 diabetes. Melanie Davies, Professor of Diabetes Medicine at the University of Leicester, said: “Many of my patients tell me they have difficulty taking their insulin at exactly the same time each day.
Some patients find it hard to take their insulin at the same time every day
Many of my patients tell me they have difficulty taking their insulin at exactly the same time each day.
“This is often for reasons which we can all sympathise with. We might get stuck in traffic picking the children up from school or our shifts at work might change.
“Now for the first time insulin- dependent diabetes patients will have the peace of mind that their blood sugar is still under control if they are, on occasion, not able to take their insulin dose at the same time each day.”
Doctors believe the new drug could help slash the 24,000 unnecessary and premature deaths from diabetes each year.
It is also expected to lead to huge savings for the NHS. Eighty per cent of the £10billion a year spent on diabetes goes on treating avoidable complications.
The new drug could help slash the 24,000 premature deaths from diabetes each Tresiba, developed by Novo Nordisk, was approved by the European Commission in January. Cathy Moulton, a clinical adviser at Diabetes UK, said: “Trials of the drug have shown rates of night-time hypoglycaemia were reduced by about a quarter.” But she advised patients to check with their doctor first to see if it is necessary for them to switch to the new drug as existing treatments may be sufficient.
“If patients are recommended to switch to this insulin it should only be because their blood glucose levels are not being controlled well enough by their current insulin,” she said.
Night-time hypoglycaemia is estimated to be responsible for six per cent of deaths in diabetics under 40.
It costs the NHS an estimated £1,000 per hospital admission and emergency admissions have risen by 26 per cent in five years.